Abstract
The p38 mitogen activated protein (MAP) kinase is an integral enzyme involved in the production of a wide variety of pro-inflammatory cytokines from various cell types. The identification of this kinase and of the diaryl imidazole containing inhibitor, SB203580, initiated an intense discovery effort in this field. Numerous inhibitors were subsequently produced containing replacements for the imidazole, as well as some of the pharmacophores attached to it. During this time many other classes of potent p38 inhibitors emerged containing scaffolds and binding components not found in the diaryl imidazole group. This review summarizes nine of those classes. At least one of these classes requires the kinase to undergo reorganization prior to binding. From this diverse set of inhibitors four compounds have been reported advancing into human clinical trials.
Keywords: kinase inhibition, anti-cancer agents, purine-derived compounds, cell cycle, solid phase synthesis, biological activity
Current Topics in Medicinal Chemistry
Title: The Non-Diaryl Heterocycle Classes of p38 MAP Kinase Inhibitors
Volume: 2 Issue: 9
Author(s): Pier F. Cirillo, Christopher Pargellis and John Regan
Affiliation:
Keywords: kinase inhibition, anti-cancer agents, purine-derived compounds, cell cycle, solid phase synthesis, biological activity
Abstract: The p38 mitogen activated protein (MAP) kinase is an integral enzyme involved in the production of a wide variety of pro-inflammatory cytokines from various cell types. The identification of this kinase and of the diaryl imidazole containing inhibitor, SB203580, initiated an intense discovery effort in this field. Numerous inhibitors were subsequently produced containing replacements for the imidazole, as well as some of the pharmacophores attached to it. During this time many other classes of potent p38 inhibitors emerged containing scaffolds and binding components not found in the diaryl imidazole group. This review summarizes nine of those classes. At least one of these classes requires the kinase to undergo reorganization prior to binding. From this diverse set of inhibitors four compounds have been reported advancing into human clinical trials.
Export Options
About this article
Cite this article as:
Cirillo F. Pier, Pargellis Christopher and Regan John, The Non-Diaryl Heterocycle Classes of p38 MAP Kinase Inhibitors, Current Topics in Medicinal Chemistry 2002; 2 (9) . https://dx.doi.org/10.2174/1568026023393390
DOI https://dx.doi.org/10.2174/1568026023393390 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Candidiasis: A Fungal Infection- Current Challenges and Progress in Prevention and Treatment
Infectious Disorders - Drug Targets Tuning Immune Suppression in Systemic Autoimmunity with Self-Derived Peptides
Inflammation & Allergy - Drug Targets (Discontinued) Growth Factors and Chemokines: A Comparative Functional Approach Between Invertebrates and Vertebrates
Current Medicinal Chemistry Patent Selections
Recent Patents on Anti-Infective Drug Discovery Angiotensin-Converting Enzyme 2 Roles in the Pathogenesis of COVID-19
Current Hypertension Reviews Patent Selections
Recent Patents on DNA & Gene Sequences Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology
Recent Patents on Anti-Cancer Drug Discovery Anti-inflammatory Property of AMP-activated Protein Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Scaffold-based Drug Delivery for Cartilage Tissue Regeneration
Current Pharmaceutical Design Synthesis and Pharmacological Studies of Novel 3-Substituted Indole Derivatives as Potential Anti-Inflammatory and Analgesic Agents
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Molecular and Vascular Targets in the Pathogenesis and Management of the Hypertension Associated with Preeclampsia
Cardiovascular & Hematological Agents in Medicinal Chemistry The “Invisible Proteome”: How to Capture the Low-Abundance Proteins Via Combinatorial Ligand Libraries
Current Proteomics Influence of Gold Nanoparticle Tagged Snake Venom Protein Toxin NKCT1 on Ehrlich Ascites Carcinoma (EAC) and EAC Induced Solid Tumor Bearing Male Albino Mice
Current Drug Delivery Use of Biguanides and the Risk of Colorectal Cancer: A Register-Based Cohort Study
Current Drug Safety Immunity to Systemic Salmonella Infections
Current Molecular Medicine Prostaglandin E2 Binding Peptide: a Potential Modulatory Agent which Acts Through Suppressing NF-kappaB Signaling in RA
Protein & Peptide Letters Is Helicobacter pylori the Infectious Trigger for Headache?: A Review
Infectious Disorders - Drug Targets Neurodegeneration and Neuroprotection in Multiple Sclerosis
Current Pharmaceutical Design